Analyst Price Target is $40.57
▲ +176.94% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Pliant Therapeutics in the last 3 months. The average price target is $40.57, with a high forecast of $45.00 and a low forecast of $33.00. The average price target represents a 176.94% upside from the last price of $14.65.
Current Consensus is
Buy
The current consensus among 9 polled investment analysts is to buy stock in Pliant Therapeutics. This Buy consensus rating has held steady for over two years.
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Read More